63 results on '"Burge, Russel"'
Search Results
2. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
3. Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data
4. Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program.
5. Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program.
6. Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry.
7. Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry
8. Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
9. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings
10. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
11. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
12. Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.
13. A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
14. Burden of Disease for Psoriasis in Argentina, Brazil, Colombia, and Mexico.
15. Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
16. Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis.
17. Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool.
18. Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
19. Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan.
20. Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
21. Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J).
22. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
23. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
24. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
25. Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
26. Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey.
27. Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry
28. Burden and Disease Characteristics of Patients with Psoriatic Arthritis: A Population-based Cross-sectional Study.
29. 43015 Ixekizumab real-world effectiveness at 24 weeks in patients with psoriasis: Data from the United States Taltz Customer Support Program.
30. The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS).
31. The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health.
32. Burden and Disease Characteristics of Patients with Psoriatic Arthritis: A Population-based Cross-sectional Study
33. Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice
34. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis
35. Lifestyle-Related Metabolic Disorders, Osteoporosis, and Fracture Risk in Asia: A Systematic Review.
36. Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis.
37. Lifestyle-Related Metabolic Disorders, Osteoporosis, and Fracture Risk in Asia: A Systematic Review
38. Characteristics of hip fracture patients with and without muscle atrophy/weakness: Predictors of negative economic outcomes
39. Retrospective database study to assess the economic impact of hip fracture in the United Kingdom
40. 26750 Cumulative clinical benefits of biologic treatments for psoriasis over 1 year.
41. 26718 Comparison of long-term treatment patterns between ixekizumab and secukinumab users among biologic-experienced psoriasis patients.
42. 26654 Ixekizumab demonstrates greater medication adherence, persistence, and longer monotherapy duration than secukinumab, adalimumab, ustekinumab, and etanercept up to 3 years in the treatment of psoriasis: Real-world results.
43. 26158 The patient-reported burden of alopecia areata by current severity: A real-world study in the US.
44. 26032 Sustained and rapid improvements in patient reported outcomes for moderate-to-severe psoriasis patients with moderate and high BSA treated with ixekizumab: Side-by-side results from UNCOVER-3 and IXORA-S.
45. 25799 Efficacy and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis with and without psoriatic arthritis at baseline: Results from UNCOVER studies through 5 years.
46. 25792 Improvements in BSA associate with improvements in itch and quality of life in patients with moderate-to-severe psoriasis treated with ixekizumab or guselkumab through 24 weeks.
47. 25748 Ixekizumab sustained complete clearance, itch resolution, and improved quality of life for moderate-to-severe psoriasis patients who achieved rapid, high skin clearance.
48. 26648 Real-world comparison of monotherapy and concomitant medication use with biologic therapies for psoriasis: Ixekizumab versus guselkumab.
49. 25805 Ixekizumab provides more durable improvements in skin clearance, itch, and quality of life than guselkumab in patients with moderate-to-severe psoriasis: 24-week results from IXORA-R.
50. 16007 Ixekizumab demonstrated longer medication persistence than other biologics in the treatment of psoriasis patients: Results from IBM MarketScan databases.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.